# Revolution Medicines turned the most notorious undruggable target in oncology into a whole drug class - Date: 2026-04-15 - Category: Biotech & Life Sciences Daraxonrasib turned RAS from oncology's most notorious punchline into a $2B pipeline bet. The survival benefit is real. The question is whether it's a platform or a one-drug story. ---